Jurgi Camblong Sells 20,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the chairman owned 3,492,822 shares in the company, valued at approximately $23,157,409.86. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total transaction of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Trading Down 0.4%

SOPH stock opened at $5.55 on Thursday. SOPHiA GENETICS SA has a 1-year low of $2.92 and a 1-year high of $6.77. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The business’s 50 day moving average is $5.44 and its 200-day moving average is $5.09. The firm has a market cap of $465.59 million, a P/E ratio of -10.67 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares during the last quarter. Principal Financial Group Inc. increased its position in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares in the last quarter. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS in the 1st quarter valued at about $50,000. Finally, Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the third quarter worth about $49,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SOPH shares. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright initiated coverage on shares of SOPHiA GENETICS in a report on Monday, July 20th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus target price of $9.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.